Cargando…

The Antithrombin Effect of Ankaferd Hemostat (ABS) Is Related to the High Iron Content of the Medicine

Detalles Bibliográficos
Autores principales:	Okay, Mufide, Ozturk, Yusuf, Haznedaroglu, Ibrahim C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2019
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6714915/ https://www.ncbi.nlm.nih.gov/pubmed/30808215 http://dx.doi.org/10.1177/1076029618824416

Ejemplares similares

Ankaferd hemostat: from molecules to medicine
por: ÇİFTÇİLER, Rafiye, et al.
Publicado: (2020)

Antineoplastic Effects of Ankaferd Hemostat
por: Malkan, Umit Yavuz, et al.
Publicado: (2022)

Endothelial Cells, Ankaferd Hemostat, and Estradiol
por: Ardıçoğlu, Yasemin, et al.
Publicado: (2016)

Antiinfective and wound-healing pleiotropic actions of Ankaferd hemostat
por: HAZNEDAROĞLU, İbrahim Celalettin, et al.
Publicado: (2020)

Pharmacobiological management of hemostasis within clinical backgrounds via Ankaferd hemostat (Ankaferd blood stopper)
por: Ciftciler, Rafiye, et al.
Publicado: (2020)

Qualitative/Chemical Analyses of Ankaferd Hemostat and Its Antioxidant Content in Synthetic Gastric Fluids
por: Koluman, Ahmet, et al.
Publicado: (2016)

Effects of Ankaferd Hemostat on Helicobacter pylori strains and antibiotic resistance
por: ÇİFTÇİLER, Rafiye, et al.
Publicado: (2019)

Antibacterial Activities of Ankaferd Hemostat (ABS) on Shiga Toxin-Producing Escherichia coli and Other Pathogens Significant in Foodborne Diseases
por: Koluman, Ahmet, et al.
Publicado: (2017)

Ankaferd hemostat (ABS) as a potential mucosal topical agent for the management of COVID-19 syndrome based on its PAR-1 inhibitory effect and oestrogen content
por: Beyazit, Fatma, et al.
Publicado: (2020)

Aggressive Clinicopathological Course of Myeloma with t(3;16) (q21;q22) Cytogenetic Abnormality
por: Bozkurt, Süreyya, et al.
Publicado: (2019)

Tumor Lysis Syndrome Due to Targeting of Hepatocellular Carcinoma Associated with Chronic Myelomonocytic Leukemia
por: Okay, Müfide, et al.
Publicado: (2019)

Effects of Ankaferd Hemostat on red blood cell aggregation: a hemorheological study
por: ÇİFTÇİLER, Rafiye, et al.
Publicado: (2019)

Growth inhibitory activity of Ankaferd hemostat on primary melanoma cells and cell lines
por: Turk, Seyhan, et al.
Publicado: (2017)

A New Candidate as a Hemostatic Agent for Difficult Situations During Variceal Bleeding: Ankaferd Blood Stopper
por: Ozaslan, Ersan, et al.
Publicado: (2011)

Generation of Chimeric “ABS Nanohemostat” Complex and Comparing Its Histomorphological In Vivo Effects to the Traditional Ankaferd Hemostat in Controlled Experimental Partial Nephrectomy Model
por: Huri, Emre, et al.
Publicado: (2013)

Analysis of the Antiproliferative Effect of Ankaferd Hemostat on Caco-2 Colon Cancer Cells via LC/MS Shotgun Proteomics Approach
por: Koçak, Engin, et al.
Publicado: (2019)

In Vitro Efficacy of the Ankaferd Galenic Hemostatic Extract as a Germicidal Agent
por: METİN, Bayram, et al.
Publicado: (2016)

Proteomic and transcriptomic analyses to explain the pleiotropic effects of Ankaferd blood stopper
por: Simsek, Cem, et al.
Publicado: (2017)

Oral High-Dose Ankaferd Administration Effects on Gastrointestinal System
por: Akbal, Erdem, et al.
Publicado: (2013)

Calculation of the Correct Angle of Bifurcation Predicts the Atherosclerotic Lesion Location More Accurately
por: Ozgeyik, Mehmet, et al.
Publicado: (2021)

Successful Application of Ankaferd Blood Stopper in a Patient with Lower Gastrointestinal Bleeding
por: Beyazit, Yavuz, et al.
Publicado: (2011)

Comparison of hemostatic efficacy of topical Ankaferd Blood Stopper on heparinized and nonheparinized rats in bleeding related to liver injury
por: Ergin, Metin, et al.
Publicado: (2021)

Effect of the plant-based hemostatic agent Ankaferd Blood Stopper® on the biocompatibility of mineral trioxide aggregate
por: Dinçol, Muzaffer Emir, et al.
Publicado: (2016)

Proper diagnosis of antithrombin III deficiency
por: Özdemir, Zehra Narlı, et al.
Publicado: (2017)

Effectiveness of Ankaferd BloodStopper in Prophylaxis and Treatment of Oral Mucositis in Childhood Cancers Evaluated with Plasma Citrulline Levels
por: Patıroğlu, Türkan, et al.
Publicado: (2018)

Antithrombin, COVID-19, and Fresh Frozen Plasma Treatment
por: Mungmungpuntipantip, Rujitttika, et al.
Publicado: (2021)

Successful use of an antithrombin for heparin resistance with andexanet alfa
por: Honda, Jun, et al.
Publicado: (2023)

Hemostatic powder facts
por: Wagner, David R., et al.
Publicado: (2019)

The Dual Diverse Dynamic Reversible Effects of Ankaferd Blood Stopper on EPCR and PAI-1 Inside Vascular Endothelial Cells With and Without LPS Challenge
por: Karabıyık, Afife, et al.
Publicado: (2012)

Hemostatic alterations in COVID-19
por: Peyvandi, Flora, et al.
Publicado: (2020)

Comparing therapeutic effects of alternate day versus daily oral iron in women with iron deficiency anemia: A retrospective cohort study
por: Uçan, Anil, et al.
Publicado: (2023)

Ankaferd Influences mRNA Expression of Iron-Regulated Genes During Iron-Deficiency Anemia
por: Gulec, Afife, et al.
Publicado: (2017)

Direct antimicrobial activity of antithrombin?
por: Wiedermann, Christian J, et al.
Publicado: (2010)

Ultrastructural analyses of the novel chimeric hemostatic agent generated via nanotechnology, ABS nanohemostat, at the renal tissue level
por: Huri, Emre, et al.
Publicado: (2016)

Demonstration of the histopathological and immunohistochemical effects of a novel hemostatic agent, ankaferd blood stopper, on vascular tissue in a rat aortic bleeding model
por: Kandemir, Ozer, et al.
Publicado: (2010)

The Effectiveness of a New Hemostatic Agent (Ankaferd Blood Stopper) for the Control of Bleeding following Tooth Extraction in Hemophilia: A Controlled Clinical Trial
por: Kazancıoğlu, Hakkı Oğuz, et al.
Publicado: (2013)

Impact of convalescent and nonimmune plasma on mortality of patients with COVID-19: a potential role for antithrombin
por: Gazzaruso, Carmine, et al.
Publicado: (2021)

Genetic testing of hereditary antithrombin deficiency in a large US pedigree using saliva samples
por: Mulder, René, et al.
Publicado: (2020)

The impact of JAK/STAT inhibitor ruxolitinib on the genesis of lymphoproliferative diseases
por: TÜRK, Can, et al.
Publicado: (2019)

Hemostatic Tampon to Reduce Bleeding following Tooth Extraction
por: Kalantar Motamedi, M H, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_bd72im2gpp5bpqdkbblskbkb7c